Back to search

National and Kapodistrian University of Athens

Μελέτη μηχανισμών αντίστασης του anti-PD-1 σε ασθενείς με μεταστατικό μελάνωμα

Abstract

dc:description

Immune checkpoint inhibitors (ICIs) have significantly improved outcomes in melanoma by enhancing adaptive immunity, but not all patients benefit equally. While some experience early relapses, others maintain long-term responses, even after stopping treatment. To uncover cellular and molecular markers in the blood that may distinguish advanced (stage III) from metastatic (stage IV) melanoma and predict immune escape mechanisms, we analyzed 100 consecutive patients diagnosed with stage III/IV melanoma who were about to begin ICI therapy. Before initiating treatment, all patients underwent multiparameter flow cytometry and immune cell isolation using standard conjugated antibodies. Based on recurrence-free or progression-free survival (RFS/PFS), we retrospectively selected patients with the most distinct clinical outcomes. Specifically, we focused on two subgroups — seven strong responders and seven non-responders — and conducted bulk RNA sequencing (RNA-seq) of their circulating CD4+ T cells. We used differential expression analysis (DEA) and Gene Ontology (GO) enrichment to identify gene expression differences and related pathways, comparing stage III vs. IV disease and long-term vs. early non-responders.Although the overall number of circulating immune cells was similar across groups, transcriptomic analyses revealed distinct gene expression profiles. There were 189 vs. 92 differentially expressed genes (DEGs) in stage IV vs. III patients, and 101 vs. 47 DEGs in early progressors vs. long-term responders. These genes were associated with specific biological pathways. In metastatic cases (stage IV), upregulated pathways included: Inflammatory response (e.g., ADGRE5/2, CYBA, GRN, HMOX1, IRF5, ITGAM); Adaptive immunity (e.g., CD1C, CD74,CYBB, NCF2, S100A8/9, BCL3); T-cell activation (e.g., BCL3, CD1C, CD74, FCER1G, FGL2) and Lipid metabolism and catabolism (e.g., ARF3, GPX1, CTSA, PNPLA2, ABHD4). In early ICI non-responders, key upregulated pathways included: Immune effector processing (e.g., HLA-DQA1/DQB1, HLA-DRA, HLA-DRB1/DRB5, NKG7, TYROBP); PD-1 signaling (e.g., HLA-DQA1/DQB1, HLA-DRA, HLA-DRB1/DRB5); Interferon signaling (e.g., HLA-DQA1/DQB1, HLA-DRA, HLA-DRB1/DRB5, NCAM1, IFITM3); Positive regulation of T-cell activation (e.g., BCL6, HLA-DQA1/DQB1, HLA-DRA, HLA-DRB1/DRB5, HAVCR2), and CD28 co-stimulation (e.g., HLA-DQA1/DQB1, HLA-DRA, HLA-DRB1/DRB5), all indicative of immune dysregulation or exhaustion. Our findings suggest that specific gene expression patterns and immune-related pathways in peripheral CD4+ T cells can help predict melanoma stage and resistance to immunotherapy.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2026

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Palli, Eleni
  • Πάλλη, Ελένη

Subjects

dc:subject × 20

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/60914

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Palli, Eleni; Πάλλη, Ελένη. Μελέτη μηχανισμών αντίστασης του anti-PD-1 σε ασθενείς με μεταστατικό μελάνωμα. National and Kapodistrian University of Athens, 2026. http://hdl.handle.net/10442/hedi/60914